

miR-136 Targets MIEN1 and Involves the Metastasis of Colon Cancer by Suppressing Epithelial-to-Mesenchymal Transition [Retraction]

Ren H, Qi Y, Yin X, Gao J. *Onco Targets Ther.* 2018;11:67-74.

We, the Editors and Publisher of *OncoTargets and Therapy*, have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from Figures 1 and 3 with images from other unrelated articles. Specifically,

- Western blot bands and the background from images in Figure 1B have been duplicated with the bands and background for images from Figure 2D from Liu Y, Zhang B, Shi T, Qin H. miR-182 promotes tumor growth and increases chemoresistance of human anaplastic thyroid cancer by targeting tripartite motif 8. *Onco Targets Ther.* 2017;10:1115-1122. <https://doi.org/10.2147/OTT.S110468>.
- Images for Figure 3C have been duplicated with images for Figure 3 from Qiu, P., Xu, T., Lu, X., Yang, W., Zhang, Y., & Xu, G. (2018). MicroRNA-378 regulates cell proliferation and migration by repressing RNF31 in pituitary adenoma Retraction in /10.3892/ol.2023.14196. *Oncology Letters*, 15, 789-794. <https://doi.org/10.3892/ol.2017.7431>.
- Images for Figure 3D have been duplicated with images for Figure 2 from Wang, S., Cao, K., He, Q., Yin, Z., & Zhou, J. (2016). miR-199a-5p induces cell invasion by suppressing E-cadherin expression in cutaneous squamous cell carcinoma. *Oncology Letters*, 12, 97-101. <https://doi.org/10.3892/ol.2016.4602> and Figure 2C from Zhao, J., Li, B., Shu, C., Ma, Y., & Gong, Y. (2017). Downregulation of miR-30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer Retraction in /10.3892/ol.2023.14168. *Oncology Letters*, 14, 7437-7442. <https://doi.org/10.3892/ol.2017.7114>.

The authors did not respond to our queries and were unable to provide an explanation for the duplicated images or provide data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

<https://doi.org/10.2147/OTT.S464003>

Received: 13 February 2024
Accepted: 13 February 2024
Published: 15 February 2024

OncoTargets and Therapy 2024:17 | 11



© 2024 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).

111